PMID- 36730299
OWN - NLM
STAT- MEDLINE
DCOM- 20230515
LR  - 20231213
IS  - 1473-5741 (Electronic)
IS  - 0959-4973 (Linking)
VI  - 34
IP  - 6
DP  - 2023 Jul 1
TI  - Neutrophil-to-lymphocyte ratio predicts therapy outcomes of transarterial 
      chemoembolization combined with tyrosine kinase inhibitors plus programmed cell 
      death ligand 1 antibody for unresectable hepatocellular carcinoma.
PG  - 775-782
LID - 10.1097/CAD.0000000000001458 [doi]
AB  - The objective is to assess the predictive value of preoperative biochemical 
      markers, expressed as neutrophil-to-lymphocyte ratio (NLR), in patients with 
      unresectable hepatocellular carcinoma (uHCC) receiving a combination of tailored 
      tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) plus 
      transarterial chemoembolization (TACE). A total of 95 patients with uHCC treated 
      with TACE + TKIs + ICIs in our hospital between March 2018 and October 2021 were 
      included in this retrospective study. The prognosis of the patients was analyzed 
      based on NLRs. Overall survival (OS), progression-free survival (PFS), and 
      adverse events (AEs) were evaluated. Univariate and multivariate analyses were 
      used to determine factors affecting survival. Patients with a low pretreatment 
      NLR (NLR </= 2.22) had significantly longer OS (25.8 months vs. 16.4 months; P = 
      0.000) and PFS (14.0 months vs. 11.1 months; P = 0.002). In multivariate 
      analysis, two independent factors affecting PFS were identified: hepatitis B 
      virus infection and NLR. Three independent factors affected OS: tumor size, 
      Eastern Cooperative Oncology Group performance, and NLR. All AEs were tolerable, 
      whereas NLR could be suspected as an indicator of immunotherapy-related AEs. A 
      lower pretreatment NLR (</=2.22) might indicate a better prognosis for patients 
      with uHCC treated with TACE + TKIs + ICIs. NLR could provide better guidance for 
      clinicians when evaluating the prognosis of patients with uHCC treated with TACE 
      + TKIs + ICIs and making clinical treatment decisions.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Zheng, Xin
AU  - Zheng X
AD  - Department of Hepatopancreatobilary Surgery, The First College of Clinical 
      Medical Sciences, China Three Gorges University, Yichang.
FAU - Qian, Kun
AU  - Qian K
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology.
AD  - Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221117
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 0 (Tyrosine Kinase Inhibitors)
RN  - 0 (Ligands)
RN  - 0 (Immunoglobulins)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Neutrophils
MH  - Tyrosine Kinase Inhibitors
MH  - *Liver Neoplasms/drug therapy
MH  - Retrospective Studies
MH  - Ligands
MH  - *Chemoembolization, Therapeutic
MH  - Lymphocytes/pathology
MH  - Immunoglobulins
MH  - Apoptosis
EDAT- 2023/02/03 06:00
MHDA- 2023/05/15 06:42
CRDT- 2023/02/02 13:53
PHST- 2023/05/15 06:42 [medline]
PHST- 2023/02/03 06:00 [pubmed]
PHST- 2023/02/02 13:53 [entrez]
AID - 00001813-202307000-00007 [pii]
AID - 10.1097/CAD.0000000000001458 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2023 Jul 1;34(6):775-782. doi: 10.1097/CAD.0000000000001458. 
      Epub 2022 Nov 17.